CHU Timone, Pôle Oncologie, Spécialités médicales et chirurgicales, Service d’oncologie digestive, 264 rue Saint Pierre, 13385 Marseille cedex 5, France
Aix-Marseille Université, Marseille, France
- Key words: pancreatic cancer, chemotherapy, chemo-radiotherapy, adjuvant treatment, gemcitabine
- DOI : 10.1684/hpg.2017.1515
- Page(s) : 808-12
- Published in: 2017
An efficient carcinologic surgery will not be possible for 80 % of patients with pancreatic adenocarcinoma. After surgical resection, we observe a high rate of locoregional or metastatic relapses. Numerous adjuvant therapeutic trials have been conducted to establish recommendations in Europe. Chemoradiotherapy doesn’t improve survival in two out of three randomized trials and in a meta-analysis. Since 2004, adjuvant chemotherapy with either 5FU or gemcitabine, or both is the reference treatment for patients with resected pancreatic adenocarcinoma with or without lymph node involvement. Gemcitabine is the standard for metastatic patients and new predictive factors for efficacy are under evaluation.